R-Tech Ueno Completes Phase 1 Clinical Study Of RK-023

R-Tech Ueno has completed phase 1 clinical study of RK-023, a therapeutic drug of androgenetic alopecia.

The phase 1 clinical study of RK-023 was a patch test, single dose and 5-day repeated dose study. Since no serious adverse event occurred in each test, RK-023 seems to hardly cause any safety problem in the human body.

RK-023 study was a randomized, placebo-controlled, double blind study to evaluate the safety and pharmacokinetics of the drug.

Yukihiko Mashima, representative director and president of R-Tech Ueno, said: We are pleased to announce the successful completion of a phase 1 clinical study on our self-developed RK-023 that focuses on the dermatology field. We intend to start a phase 2 clinical study in Japan as scheduled and at the same time proceed with full-scale negotiations for partnership at home and abroad.